We describe a case of an anti-HBs-positive patient who experienced hepatitis B reactivation 18 months after the discontinuation of rituximab and after 12 months of lamivudine prophylaxis. The patient carried a hepatitis B genotype D virus harbouring a single immune escape mutation, sT118K. No consensus guidelines regarding the optimal length of treatment or the best elective drug have been defined for antiviral prophylaxis for HBsAg-negative, anti-HBc- and/or anti-HBs-positive patients undergoing immunosuppressive treatment. Screening based on HBV serological markers and HBV DNA testing is a critical issue to recognise hepatitis B reactivation as early as possible. Furthermore, it is of outstanding importance to identify alternative markers (e.g. cccDNA, HBV core related antigen, etc.), that could be predictive of HBV reactivation.

Ceccarelli, L., Salpini, R., Sarmati, L., Svicher, V., Bertoli, A., Sordillo, P., et al. (2011). Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy. JOURNAL OF INFECTION, 65(2) [10.1016/j.jinf.2011.11.021].

Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy

Salpini, R;SARMATI, LOREDANA;SVICHER, VALENTINA;BERTOLI, ADA;SORDILLO, PASQUALE;PERNO, CARLO FEDERICO;ANDREONI, MASSIMO;SARRECCHIA, CESARE
2011-11-23

Abstract

We describe a case of an anti-HBs-positive patient who experienced hepatitis B reactivation 18 months after the discontinuation of rituximab and after 12 months of lamivudine prophylaxis. The patient carried a hepatitis B genotype D virus harbouring a single immune escape mutation, sT118K. No consensus guidelines regarding the optimal length of treatment or the best elective drug have been defined for antiviral prophylaxis for HBsAg-negative, anti-HBc- and/or anti-HBs-positive patients undergoing immunosuppressive treatment. Screening based on HBV serological markers and HBV DNA testing is a critical issue to recognise hepatitis B reactivation as early as possible. Furthermore, it is of outstanding importance to identify alternative markers (e.g. cccDNA, HBV core related antigen, etc.), that could be predictive of HBV reactivation.
23-nov-2011
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICA
English
Con Impact Factor ISI
Ceccarelli, L., Salpini, R., Sarmati, L., Svicher, V., Bertoli, A., Sordillo, P., et al. (2011). Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy. JOURNAL OF INFECTION, 65(2) [10.1016/j.jinf.2011.11.021].
Ceccarelli, L; Salpini, R; Sarmati, L; Svicher, V; Bertoli, A; Sordillo, P; Ricciardi, A; Perno, Cf; Andreoni, M; Sarrecchia, C
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
late hepatitis b.pdf

solo utenti autorizzati

Licenza: Copyright dell'editore
Dimensione 152.68 kB
Formato Adobe PDF
152.68 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

Questo articolo è pubblicato sotto una Licenza Licenza Creative Commons Creative Commons

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/51801
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 37
  • ???jsp.display-item.citation.isi??? 34
social impact